Immunoediting in Cutaneous Squamous Carcinogenesis
Cutaneous squamous cell carcinoma (cSCC) is the second most common cancer, with ~700,000 cases, ~3,000 deaths, and billions of dollars in annual treatment-associated costs in the U.S. Escape from immunosurveillance, a hallmark of cancer, is one of the defining steps in the progression from in situ disease (SCCIS) to cSCC. We will define the steps underlying this escape in SCCIS, with the goal of developing novel immunomodulatory chemoprevention therapeutics.
— Matthew L. Hedberg, M.D., Ph.D.
- University of Pennsylvania
- Research Grant
Exploring Gene Expression Patterns and Biomarkers of Disease Severity in Central Centrifugal Cicatricial Alopecia
Central centrifugal cicatricial alopecia (CCCA), which has been associated with uterine fibroids, is unlike other scarring alopecias because fibrosis rather…
Characterizing the Microbiome in Postmenopausal Women with Vulvar Lichen Sclerosus
Vulvar lichen sclerosus is a chronic inflammatory condition that leads to scarring, obliteration of normal vulvar architecture, dyspareunia, and significant…
Cell Signaling Changes Induced by Surgical Debulking May Improve Response to Smoothened Inhibitor Therapy
Smoothened (SMO) inhibitors, such as vismodegib, are effective treatments for locally advanced basal cell carcinomas (BCCs). However, recurrences are frequent…